Stock Ratings / Health Care / PAVM / financials

MODD (36) RVP (33) CTSO (21) CNSY (36) ⌘ Pro Terminal →

PAVmed Inc. (PAVM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is PAVmed Inc. (PAVM)?

In FY 2025 (10-K), PAVM converted $1.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.97 -5.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

PAVmed Inc. (PAVM) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $15.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAVM)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How PAVM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.5M

FY24

Rev $3.0M

FY25

Rev $71.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$71.0K	-50%	-80%	-$3.8M	-$5.2M	-45%
FY 2024	$3.0M	-50%	-80%	$32.0M	-$33.6M	-45%
FY 2023	$2.5M	8%	-80%	-$66.3M	-$52.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PAVM)

✓Walkthrough of PAVM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAVM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.27%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.00H $2.08L $1.95C $1.97VOL 6.5K

RES: $4.44SUP: $1.61SMA50: $3.57SMA200: $6.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAVM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAVM Butterfly Map → + Track PAVM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PAVM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAVM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAVM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAVM)

Health Care Rank #935 of 1016 ⚔️ MODD vs PAVM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAVM vs. MODD, RVP, CTSO, CNSY)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PAVmed Inc. (PAVM) ranks #935 by composite RQD confidence (31/100, grade E) and #856 by equity capitalization ($15.8M). Within this direct 5-issuer industry benchmark cohort, PAVM leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. MODD currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with PAVM at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAVM ACTIVE PAVmed Inc.	E	31/100	—	-30.0%	-35.0%	-5.29%	$15.8M	Benchmark Subject
MODD Modular Medical Inc.	D-	36/100	—	—	-35.0%	-9.95%	$16.3M	/modd-vs-pavm →
RVP Retractable Technologies Inc.	E	33/100	—	0.1%	-23.3%	-1.15%	$17.3M	/rvp-vs-pavm →
CTSO Cytosorbents Corporation	E	21/100	—	71.5%	-35.0%	-16.03%	$13.9M	/ctso-vs-pavm →
CNSY Cerenome Inc.	D-	36/100	—	—	-35.0%	0.00%	$13.2M	/cnsy-vs-pavm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001624326

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PAVmed Inc. (PAVM) reported GAAP revenue of $71.0K (-97.6% vs. FY2024 revenue of $3.0M , and -97.1% cumulative change since FY2023) , GAAP net income of -$3.8M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+84.4% YoY). On the balance sheet, PAVM closed FY2025 with $38.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$71.0K	-$3.8M	-$5.2M	-$5.2M	$38.8M	—
FY2024 (FY)	2024-12-31	$3.0M	$32.0M	-$33.6M	-$33.6M	$30.7M	—
FY2023 (FY)	2023-12-31	$2.5M	-$66.3M	-$52.0M	-$52.0M	—	—

3. PAVM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAVM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PAVmed Inc. (NASDAQ: PAVM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.97 (-5.29% 1D, market cap $15.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PAVM ranks #935 in composite RQD confidence.

How does PAVM compare to MODD and RVP in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PAVM carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, MODD (Modular Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $16.3M) and RVP (Retractable Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -23.3%, cap $17.3M). Among the 5-stock peer group, PAVM leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PAVM?

Per PAVM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001624326), PAVmed Inc. generated $71.0K in revenue (-97.6% YoY), -$3.8M in net income, and -$5.2M in free cash flow against $38.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PAVM trading relative to its 50-day, 200-day, and 52-week technical levels?

PAVM last traded at $1.97 (-5.29% on volume of 5,357 shares), positioning the stock -44.82% below its 50-day simple moving average ($3.57) and -70.02% below its 200-day simple moving average ($6.57). Across its 52-week range of $1.84 to $28.44, PAVM sits at the 0.5% percentile with a 14-day RSI of 26.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.22).

PAVM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is PAVmed Inc. (PAVM)?

In FY 2025 (10-K), PAVM converted $1.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: PAVM RQD Cockpit PAVM 12M Forecast PAVM Earnings & Move PAVM Dividends & DRIP PAVM Insiders & 13F PAVM Whale Options PAVM Profit Sankey PAVM News & Why